Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Q2 2025 Earnings Call Transcript February 10, 2025 The Hain Celestial Group, Inc. misses on earnings expectations. Reported EPS is $-1.15359 EPS, expectations were $0.12. Operator: Good day, everyone, ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for fo ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The Hain Celestial Group, Inc. ( NASDAQ: HAIN) Q2 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Alexis Tessier - VP, IR Wendy Davidson - President & CEO Lee Boyce - CFO ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...